Some Fort Dodge Animal Health products will be made by Pfizer Inc. in the future as the result of a complex transaction that will eventually result in Boehringer Ingelheim taking over the local veterinary medicine plants.

West Nile Innovator, a vaccine developed by Fort Dodge Animal Health within the last decade to protect horses from West Nile virus, is one of those products, according to an announcement from Pfizer.

Pfizer announced its new veterinary product lines Monday, providing more details on what will result from the three-way deal involving it; Wyeth, which is the parent company of Fort Dodge Animal Health; and Boehringer Ingelheim.

What impact Monday’s announcement will have for the local plants remains unclear.

Kelly Goss, a spokeswoman for Fort Dodge Animal Health, referred all questions to Pfizer. Attempts to contact Pfizer representatives were unsuccessful.

Amy Kunkel, a spokeswoman for Boehringer Ingelheim, didn’t return a call seeking comment.

In January, Pfizer announced that it would buy Wyeth for $68 billion.

To get regulatory approval for the deal, Pfizer had to unload some of its animal health properties. Thus, it struck a deal with Boehringer Ingelheim.

That company, based in Germany, is buying Fort Dodge Animal Health’s main plant at 800 Fifth St. N.W. and its Riverside plant on Riverside Drive.

However, Pfizer is keeping some of the Fort Dodge Animal Health products.

”We’re extremely proud to offer our customers even more best-in-class and innovative products,” Clint Lewis, president of U.S. operations for Pfizer Animal Health, said in written statement. ”The products, services and expertise we are gaining strengthen what is already a robust U.S. portfolio and will enhance our leading position in the animal health marketplace.”

The announcement from Pfizer listed 10 Fort Dodge Animal Health product lines it will now make. Those products are for horses, cattle, hogs, chickens and dogs.

Contact Bill Shea at (515) 573-2141 or bshea@messengernews.net.